What is PulseMedica?
PulseMedica is a specialized medical technology firm focused on the development of proprietary real-time 3D imaging and laser targeting systems designed for high-precision retinal surgery. The company is pioneering a next-generation ultrafast femtosecond laser ophthalmic treatment, which aims to address debilitating retinal conditions such as age-related macular degeneration (AMD) and glaucoma. By integrating advanced imaging with laser precision, PulseMedica is addressing significant unmet needs in ophthalmology, offering potential therapeutic pathways for diseases that currently lack effective cures. Their market position is defined by a commitment to deep-tech innovation and the pursuit of transformative clinical outcomes in the global healthcare market.
How much funding has PulseMedica raised?
PulseMedica has raised a total of $11.3M across 2 funding rounds:
Angel/Seed
$2.6M
Other Financing Round
$8.7M
Angel/Seed (2022): $2.6M, investors not publicly disclosed
Other Financing Round (2024): $8.7M led by Saltagen Ventures, Startup TNT, and Threshold Impact
Key Investors in PulseMedica
Saltagen Ventures
Saltagen Ventures empowers early-stage deep biotechnology startups to grow their businesses globally, focusing on the North American and Asian markets.
Startup TNT
Startup TNT is dedicated to supporting Canadian startups through investment summits, local angel investing, and networking events aimed at fostering vibrant startup communities.
Threshold Impact
ThresholdImpact is a company focused on sustainable and profitable impact investing across various sectors including technology, new media, medical innovations, and social entrepreneurship.
What's next for PulseMedica?
With the recent capital deployment, PulseMedica is well-positioned to advance its clinical validation processes and scale its operational infrastructure. The strategic focus will likely shift toward optimizing the femtosecond laser platform for broader clinical adoption and securing the necessary certifications to enter key international markets. As the company moves forward, the emphasis will remain on bridging the gap between laboratory-proven technology and real-world surgical application. Investors will be closely monitoring the firm's ability to translate its technical milestones into tangible patient outcomes, which will be critical for future valuation growth and potential long-term commercialization strategies within the competitive landscape of medical device manufacturing.
See full PulseMedica company page
